What the Latest Research Says About Tysabri and PML Risk
Latest update (2026-07)
- Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Awareness to Occupational Exposure Concerns
If you or a loved one takes Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection. Decades of pharmacovigilance and post-marketing studies have established PML as a recognized risk of this therapy, leading to ongoing FDA monitoring and updated prescribing information. This page provides a neutral overview of the current research and regulatory context surrounding Tysabri and PML.
Bridging Occupational Exposure to Clinical Evidence of PML Risk
Building on the occupational context, it is essential to examine the clinical evidence regarding Tysabri and PML. Tysabri (natalizumab) is a biologic therapy approved for relapsing forms of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. For patients in North Carolina who have developed PML after Tysabri treatment, understanding the medical evidence and legal time limits for filing a claim is critical. The prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical data and postmarketing reports. Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy, as the expected benefit must be weighed against the risk of PML.
Mechanism of PML and Clinical Presentation
PML is caused by reactivation of the JC virus in immunocompromised individuals. Tysabri works by blocking alpha-4 integrin, which prevents immune cells from crossing the blood-brain barrier. This mechanism, while effective for reducing inflammation in multiple sclerosis, also impairs immune surveillance in the central nervous system, allowing JC virus to replicate unchecked. The clinical presentation of PML includes progressive neurological deficits such as weakness, vision changes, speech difficulties, and cognitive decline. Diagnosis is confirmed by MRI imaging and detection of JC virus DNA in cerebrospinal fluid. The infection typically leads to death or severe disability, as noted in the prescribing information. The adequacy of warnings regarding Tysabri and PML has been a subject of legal scrutiny. The boxed warning clearly states that healthcare professionals should "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to read a Medication Guide, understand the risks, and sign an enrollment form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether patients were fully informed of the PML risk, particularly in cases where the disease developed after prolonged therapy.
Statute of Limitations for Tysabri Claims in North Carolina
For patients in North Carolina who have been harmed by Tysabri-associated PML, settlement-related considerations include the timeline between exposure and documented harm. PML can develop after months to years of treatment. The prescribing information notes that risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency period is important for legal claims because the statute of limitations in North Carolina for personal injury cases is generally three years from the date the injury is discovered or should have been discovered. For PML, the date of discovery is often when a definitive diagnosis is made, which may occur after symptoms appear and diagnostic tests confirm the infection. Patients or their families should document the date of diagnosis, the duration of Tysabri use, and any prior immunosuppressant therapy, as these factors are central to both medical and legal assessments. In summary, Tysabri carries a known risk of PML, with specific risk factors identified in the prescribing information. The drug's labeling includes warnings and a restricted distribution program, but affected patients in North Carolina must be aware of the statute of limitations for filing claims. The timeline from exposure to harm, typically spanning years, influences when the injury is discovered and thus when the legal clock starts. Patients should consult with a qualified attorney to evaluate their individual circumstances and ensure timely action.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Tysabri PML claims in North Carolina?
In North Carolina, the statute of limitations for personal injury claims is generally three years from the date the injury is discovered or should have been discovered. For Tysabri-associated PML, the discovery date is typically when a definitive diagnosis is made. It is crucial to consult an attorney promptly to ensure your claim is filed within the legal time limit.
What are the risk factors for developing PML while on Tysabri?
The prescribing information identifies three key risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be considered when assessing the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.